Overview
Labway
?
Weixiong Ceng
See more contacts
Scientific Research and Development Services
,
Medical and Diagnostic Laboratories
,
Business Support Services
,
Professional and Commercial Equipment and Supplies Merchant Wholesalers
,
Medical research, commercial
See All Industries , Medical laboratories , Business services, nec Diagnostic equipment, medical
See Fewer Industries
See All Industries , Medical laboratories , Business services, nec Diagnostic equipment, medical
See Fewer Industries
Accounting, Tax Preparation, Bookkeeping, and Payroll Services
,
Advertising, Public Relations, and Related Services
,
Architectural, Engineering, and Related Services
,
Computer Systems Design and Related Services
,
Legal Services
,
Management, Scientific, and Technical Consulting Services
,
Other Professional, Scientific, and Technical Services
,
Specialized Design Services
?
?
?
Actual
?
Actual
$240.45 million
Actual
4.05%
$2,623
DEC
?
?
Shenzhen:301060
Dynamic search and list-building capabilities
Real-time trigger alerts
Comprehensive company profiles
Valuable research and technology reports
Financial Statements
Dun & Bradstreet collects private company financials for more than 23 million companies worldwide. Find out more.
Financial data as of December 31, 2024 (12 month period) in USD
Annual Revenue 2024
$240.45 million
USD
Actual
1 USD = 7.2455 CNY
All financial statement data is in millions except per share data | Source: Morningstar
| Cash Flow (mil) | 2024 | 2023 | 2022 |
|---|---|---|---|
| Net Operating Cash | $30 | $75 | $12 |
| Net Investing Cash | -$9 | -$55 | $25 |
| Net Financing Cash | -$25 | $6 | $7 |
| Net Change in Cash | -$4 | $27 | $43 |
| Cash at Beginning of Period | $118 | $92 | $49 |
| Cash at End of Period | $114 | $118 | $92 |
| Capital Expenditure | -$11 | -$55 | -$32 |
| Assets (mil) | 2024 | 2023 | 2022 |
|---|---|---|---|
| Current Assets | |||
| Cash and Cash Equivalents | $114 | $119 | $92 |
| Accounts Receivable | $109 | $139 | $307 |
| Inventories | $42 | $51 | $55 |
| Other Current Assets | $11 | $12 | $14 |
| Asset Summary | |||
| Total Current Assets | $276 | $321 | $468 |
| Tangible Fixed Assets | $67 | $70 | $30 |
| Intangible Assets | $3 | $4 | $2 |
| Total Assets | $2,623 | $2,987 | $3,747 |
| Liabilities (mil) | 2024 | 2023 | 2022 |
|---|---|---|---|
| Current Liabilities | |||
| Accounts Payable | $54 | $69 | $119 |
| Short-Term Debt | $13 | $25 | $21 |
| Other Current Liabilities | $18 | $19 | $56 |
| Liability Summary | |||
| Total Current Liabilities | $85 | $114 | $195 |
| Long-Term Debt | $18 | $20 | $ |
| Other Long-Term Liabilities | $3 | $1 | $ |
| Total Liabilities | $111 | $139 | $203 |
| Stakeholder's Equity (mil) | 2024 | 2023 | 2022 |
|---|---|---|---|
| Equity | |||
| Common Stock | $55 | $55 | $55 |
| Retained Earnings | $88 | $104 | $141 |
| Equity Summary | |||
| Total Equity | $229 | $246 | $285 |
| Shares Outstanding | 400,517,000 | 400,517,000 | 400,517,000 |